Fas signaling promotes motility and metastasis through epithelial- mesenchymal transition in gastrointestinal cancer

Oncogene

Volumn 32, Issue 9, 2013, Pages 1183-1192

  Zheng, H X ^a   Cai, Y D ^a,b   Wang, Y D ^a   Cui, X B ^a   Xie, T T ^a   Li, W J ^a   Peng, L ^a,c   Zhang, Y ^a,d   Wang, Z Q ^a,c   Wang, J ^a   Jiang, B ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b XIYUAN HOSPITAL   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

epithelial mesenchymal transition; Fas signaling; metastasis; motility

Indexed keywords

FAS LIGAND; I KAPPA B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OXALIPLATIN; PROTEIN BCL 2; PROTEIN BCL XL; TRANSCRIPTION FACTOR SLUG; UVOMORULIN; VIMENTIN;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INFILTRATION; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GASTROINTESTINAL MOTILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CANCER; UPREGULATION; VISCERAL METASTASIS;

ANTIGENS, CD95; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FAS LIGAND PROTEIN; GASTROINTESTINAL NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SIGNAL TRANSDUCTION;

GASTROPODA;

EID: 84874739695     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.126     Document Type: Article

References (33)

1. Curtin JF, Cotter TG. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal 2003; 15: 983-992.
2. Shinohara H, Yagita H, Ikawa Y, Oyaizu N. Fas drives cell cycle progression in glioma cells via extracellular signalregulated kinase activation. Cancer Res 2000; 60: 1766-1772.
3. Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA et al. Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocytederived macrophagesJ Immunol 2003; 170: 6209-6216.
4. Choi C, Xu X, Oh JW, Lee SJ, Gillespie GY, Park H et al. Fas-induced expression of chemokines in human glioma cells: involvement of extracellular signal-regulated Kinase1/2 and p38 mitogen-activated protein kinase. Cancer Res 2001; 61: 3084- 3091.
5. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C et al. CD95 promotes tumor growth. Nature 2010; 465: 492-496.
6. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004; 23: 3175-3185.
7. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6: 920-923.
8. Lavrik IN, Golks A, Riess D, Bentele M, Eils R, Krammer PH. Analysis of CD95 threshold signaling. J Biol Chem 2007; 282: 13664-13671.
9. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008; 13: 235-248.
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D et al. Global cancer statistics. CA: Cancer J Clin 2011; 61: 69-90.
11. Griffin MR, Bergstralh EJ, Coffey 3rd RJ, Beart Jr RW, Melton 3rd LJ. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987; 60: 2318-2324.
12. O'Brien DI, Nally K, Kelly RG, O'Connor TM, Shanahan F, O'Connell J. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin Ther Targets 2005; 9: 1031-1044.
13. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B et al. Tumor progression while on chemotherapy. Ann Surg 2004; 240: 1052-1064.
14. Kalluri R. EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest 2009; 119: 1417-1419.
15. Przybylo JA, Radisky DC. Matrix metalloproteinase-induced epithelial mesenchymal transition: tumor progression at Snail's pace. Int J Biochem Cell Biol 2007; 39: 1082-1088.
16. Turley EA, Veiseh M, Radisky DC, Bissell MJ. Mechanisms of disease: epithelialmesenchymal transition - does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 2008; 5: 280-290.
17. Huber MA, Kraut N, Beug H. Molecular requirements for epithelialmesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-558.
18. Li H, Zheng H, Liu J, Houghton J. CD95 signaling induces EMT in colon cancer cells. Gastroenterology 2011; 140: S-162.
19. Li H, Cai X, Fan X, Moquin B, Stoicov C, Houghton J. Fas Ag-FasL coupling leads to ERK1/2-mediated proliferation of gastric mucosal cells. Am J Physiol Gastrointest Liver Physiol 2008; 294: G263-G275.
20. Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase- 7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 2001; 61: 577-581.
21. Ametller E, Garcia-Recio S, Costamagna D, Mayordomo C, Ferna'ndez-Nogueira P, Carbó N et al. Tumor promoting effects of CD95 signaling inchemoresistant cells. Mol Cancer 2010; 9: 161.
22. Medici D, Hay ED, Goodenough DA. Cooperation between Snail and LEF-1 transcription factors is essential for TGF-1-induced epithelial-mesenchymal transition. Mol biol cell 2006; 17: 1871-1879.
23. Higgs HN, Peterson KJ. Phylogenetic analysis of the formin homology 2 domain. Mol Biol Cell 2005; 16: 1-13.
24. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-1784.
25. Yan W, Fu Y, Tian D, Liao J, Liu M, Wang B et al. PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells. Biochem Biophys Res Commun 2009; 382: 631-636.
26. Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003; 5: 118-125.
27. Zhu Q, Liu JY, Yang CM, Xu HW, Zhang AZ, Cui Y et al. Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroen Hepat 2006; 18: 1071-1077.
28. Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R et al. Chronic oxaliplatin resistance induces epithelial-to -mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12: 4147-4153.
29. Pryczynicz A, Guzinska-Ustymowicz K, Kemona A. Fas/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem Cytobiol 2010; 48: 425-429.
30. Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. Anticancer Res 2008; 28: 3815-3826.
31. Li H, Fan X, Stoicov C, Liu JH, Zubair S, Tsai E et al. Human and mouse colon cancer utilizes CD95 signaling for localgrowth and metastatic spread to liver. Gastroenterology 2009; 137: 934-944.
32. Wang J, Wang XY, Gong W, Mi B, Liu S, Jiang B. Increased expression of b-Catenin, phosphorylated glycogen synthase kinase 3b, cyclin D1, and c-myc in laterally spreading colorectal tumors. J Histochem Cytochem 2009; 57: 363-371.
33. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004; 10: 8465-8471.